4.8 Article

Annexin A1-containing extracellular vesicles and polymeric nanoparticles promote epithelial wound repair

期刊

JOURNAL OF CLINICAL INVESTIGATION
卷 125, 期 3, 页码 1215-1227

出版社

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI76693

关键词

-

资金

  1. NIH [RO1DK089763, RO1DK055679, RO1AI64462, DK061379, DK072564, DK079392]
  2. German Research Foundation (Deutsche Forschungsgemeinschaft, Bonn, Germany) [NE1834/1-1]
  3. William Harvey Research Foundation
  4. Wellcome Trust [10160Z13Z]
  5. Emory Digestive Diseases Research Development Center Core Grant [DK 064399]
  6. National Heart, Lung, and Blood Institute, NIH [HHSN268201000045C]
  7. Biotechnology and Biological Sciences Research Council [1368331] Funding Source: researchfish

向作者/读者索取更多资源

Epithelial restitution is an essential process that is required to repair barrier function at mucosal surfaces following injury. Prolonged breaches in epithelial barrier function result in inflammation and further damage; therefore, a better understanding of the epithelial restitution process has potential for improving the development of therapeutics. In this work, we demonstrate that endogenous annexin A1 (ANXA1) is released as a component of extracellular vesicles (EVs) derived from intestinal epithelial cells, and these ANXA1-containing EVs activate wound repair circuits. Compared with healthy controls, patients with active inflammatory bowel disease had elevated levels of secreted ANXA1-containing EVs in sera, indicating that ANXA1-containing EVs are systemically distributed in response to the inflammatory process and could potentially serve as a biomarker of intestinal mucosal inflammation. Local intestinal delivery of an exogenous ANXA1 mimetic peptide (Ac2-26) encapsulated within targeted polymeric nanoparticles (Ac2-26 Col IV NPs) accelerated healing of murine colonic wounds after biopsy-induced injury. Moreover, one-time systemic administration of Ac2-26 Col IV NPs accelerated recovery following experimentally induced colitis. Together, our results suggest that local delivery of proresolving peptides encapsulated within nanoparticles may represent a potential therapeutic strategy for clinical situations characterized by chronic mucosal injury, such as is seen in patients with IBD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据